GLP-1 has a beneficial effect on bone metabolism, possibly through the promotion of bone formulation. It has no effect on bone turnover markers or BMD. Meta-analysis shows that GLP-1RAs (liraglutide and exendin-4) have an effect on the risk of fracture. Liraglutide can significantly reduce the risk of fracture, while exendin-4 can increase the risk of fracture, but there was no significant effect in patients with T2DM. The gene discussed is GCG; the disease is type 2 diabetes mellitus.